Literature DB >> 177207

Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate.

J C Graff, P G Plagemann.   

Abstract

2-Amino-3-(hydroxynitrosoamino)propionic acid (alanosine), at a concentration as low as 2.7 muM, completely inhibits the incorporation of hypoxanthine into adenosine triphosphate by cultured Novikoff rat hepatoma cells. Alanosine inhibits the first step in the conversion of inosine monophosphate to adenosine monophosphate because inosine monophosphate, but not adenylosuccinate, accumulates in treated cells. However, the alanosine inhibition is not prevented by aspartic acid, even at a concentration of 1 mM. Alanosine treatment results in the inhibition of cell division, DNA synthesis, RNA and protein synthesis (in this order), and a depletion of the cells of adenosine triphosphate. Some of the cells accumulate in late G2 or M, but the remainder become arrested in other stages of the cell cycle. All effects are due to the inhibition of adenosine monophosphate synthesis and the consequent depletion of the adenosine triphosphate pool since they are completely prevented or reversed by addition of adenine, but not hypoxanthine, to the medium. Pyrimidine nucleotide synthesis is not significantly inhibited by alanosine, since the uridine triphosphate pool is not affected and uridine fails to reverse the cytotoxicity of alanosine. Alanosine also inhibits the transport of aspartic acid, but has a much lower affinity for this transport system than aspartic acid.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 177207

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  The treatment of acute leukemia with continuous infusion L-Alanosine.

Authors:  J K Weick; B L Tranum; F S Morrison
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

2.  Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma.

Authors:  P J Elson; L K Kvols; S E Vogl; D J Glover; R G Hahn; D L Trump; P P Carbone; J D Earle; T E Davis
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

3.  Properties of the thymidine transport system of Chinese hamster ovary cells as probed by nitrobenzylthioinosine.

Authors:  R M Wohlhueter; R Marz; P G Plagemann
Journal:  J Membr Biol       Date:  1978-09-19       Impact factor: 1.843

4.  Contragestational profile of the tumor-inhibiting agent, L-alanosine, in the rat and the hamster.

Authors:  G Galliani; A Assandri; D Barone; M Grandi; G Mistrello; G C Lancini
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Dimethylthiourea inhibition of B16 melanoma growth and induction of phenotypic alterations; relationship to ATP levels.

Authors:  A Fux; Y Sidi; G Kessler-Icekson; L Wasserman; A Novogrodsky; J Nordenberg
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.